New contest offers a platform to share, educate
and inspire others with HAE, a rare and potentially
life-threatening disease
To mark the fourth annual Hereditary Angioedema (HAE) Day, Dyax
Corp. and the HAEA today announced the launch of the HAE Hope Essay
Contest. By drawing from the inspiring stories of individuals with
HAE nationwide, the program seeks to underscore the value of hope
for those living with this potentially life-threatening condition.
HAE is characterized by spontaneous episodes of edema, or swelling,
in the face, feet, hands, throat, and abdomen.
HAEHope.com is asking eligible HAE patients across the country
to submit essays that will focus on one of two themes: 1) What I
would tell my 12 year old self about living with HAE, or 2) I have
HAE, HAE does not have me. A multi-disciplinary panel consisting of
physicians, nurses, patients and advocacy representatives will
evaluate each submission. The two winning essay entrants are
eligible to receive a cash award and will be recognized at the HAEA
Patient Summit taking place October 9-11, 2015 in Denver, Colorado.
A matching donation will be given to the HAEA Scholarship Fund in
the winners‘ names. Program submissions will be used to inform the
development of support services and educational materials for HAE
patients nationwide.
“People with HAE are very generous with one another, especially
in their willingness to provide support,” said Gustav Christensen,
President and Chief Executive Officer of Dyax. “This contest offers
a new forum for that support through creativity, self-expression
and first-hand insights about living with HAE. At Dyax, we work
closely with HAE patients to understand how this condition affects
their lives and how we can help meet their unique needs. Every day
we hear their stories of hope, courage and survival. Through this
essay program, we seek to honor those experiences and share the
inspiration that drives us towards a future where HAE no longer
limits peoples' lives.”
“For over 15 years the HAEA has helped patients and their
families overcome challenges associated with HAE and strengthen the
HAE community,” said Anthony Castaldo, President of the U.S. HAEA.
“Each person involved in this contest will be helping to inspire
others through their personal stories and raise awareness about
this rare and potentially life-threatening disease.”
Although HAE can be diagnosed through a simple blood test, the
disease is frequently undetected or misdiagnosed due to its rarity
and the similarity of its symptoms to more common conditions. In
the spirit of HAE Day, HAEHope.com seeks to raise awareness of this
little known condition and honor those individuals living with
HAE.
HAE Hope Essay Contest details can be found on www.HAEHope.com,
a support website sponsored by Dyax.
About HAE DayIn 2012, the United States Senate passed a
resolution recognizing May 16 as HAE Day. HAE Day aims to raise
awareness of HAE among the general public and medical community, in
an effort to promote better care and earlier, more accurate,
diagnosis. This event was initiated by the HAEi, the International
Patient Organization for C1-Inhibitor Deficiencies, along with the
support of its national member organizations, including the HAEA.
For more information about HAE Day, please visit
www.haeday.org.
About HAEHereditary angioedema is a rare acute
inflammatory condition characterized by episodes of severe, often
painful swelling affecting the extremities, gastrointestinal tract,
genitalia, and larynx. HAE is caused by low or dysfunctional levels
of C1 esterase inhibitor (C1-INH), a naturally occurring molecule
that inhibits plasma kallikrein, a key mediator of inflammation,
and other serine proteases in the blood. HAE is estimated to affect
up to 1 in 50,000 individuals. Learn more at www.HAEHope.com.
About the HAEAFounded and staffed by HAE patients and HAE
patient caregivers, the HAEA is a non-profit patient advocacy
organization dedicated to serving persons with angioedema. The
association provides HAE patients and their families with a support
network and a wide range of services including physician referrals,
and individualized patient support. Its goal is to increase
awareness of HAE by providing patients and physicians with
authoritative and readily accessible information. The HAEA is
committed to advancing and conducting clinical research designed to
improve the lives of HAE patients and ultimately find a cure. For
more information about the HAEA, please visit
www.haea.org.
About DyaxDyax is a biopharmaceutical company focused on
the development and commercialization of novel biotherapeutics for
unmet medical needs. The Company currently has one marketed product
for the treatment of sudden attacks of HAE in patients 12 year of
age and older, and one product candidate in clinical development
for the prevention of HAE attacks.
Dyax’s proprietary phase display technology has produced large
diverse libraries of antibodies, peptides and small proteins, and
the Company has broadly licensed this technology under its
Licensing and Funded Research Portfolio (LFRP). The current
portfolio includes one FDA approved product for which Dyax receives
royalties, and multiple product candidates in various stages of
clinical development for which the Company is eligible to receive
future milestones and/or royalties.
For additional information about Dyax, please visit
www.dyax.com.
DisclaimerThis press release contains forward-looking
statements. Statements that are not historical facts are based on
Dyax's current expectations, beliefs, assumptions, estimates,
forecasts and projections about the industry and markets in which
Dyax operates. The statements contained in this release are not
guarantees of future performance and involve certain risks,
uncertainties and assumptions, which are difficult to predict.
Therefore, actual outcomes and results may differ materially from
what is expressed in such forward-looking statements because of
risks, uncertainties and assumptions involved in any future
projections. There are many factors that could cause actual results
to differ from these forward-looking statements, including: risks
and uncertainties surrounding the launch of the HAEHope.com essay
program; risks and uncertainties relating to the clinical
development and regulatory approval of candidates in Dyax’s
internal pipeline; Dyax's dependence on the expertise, effort,
priorities and contractual obligations of third parties in the
development of candidates in Dyax’s internal pipeline and in the
marketing, sales and distribution of Dyax’s approved product;
competition from new and existing treatments for HAE; the
uncertainty of patent and intellectual property protection relating
to Dyax’s approved product, Dyax’s internal pipeline and Dyax’s
LFRP; Dyax's dependence on licensees and collaborators for
development, clinical trials, manufacturing, sales and distribution
of product candidates in the LFRP; uncertainties as to whether one
or more product candidates in the LFRP will achieve development and
regulatory milestones and be commercialized and generate royalties;
uncertainties regarding licensee’s ability to successfully market
approved product; and other risk factors described or referred to
in Item 1A, "Risk Factors" in Dyax's most recent Annual Report on
Form 10-K and other periodic reports filed with the Securities and
Exchange Commission. Dyax cautions investors not to place undue
reliance on the forward-looking statements contained in this
release. These statements speak only as of the date of this
release, and Dyax undertakes no obligations to update or revise
these statements, except as may be required by law.
HAEhope.com is sponsored by Dyax Corp. Dyax and
the Dyax logo are registered marks of Dyax Corp.
Dyax Corp.Jennifer Robinson, 617-250-5741Director, Investor
Relationsand Corporate Communicationsjrobinson@dyax.com
Dyax (NASDAQ:DYAX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Dyax (NASDAQ:DYAX)
Historical Stock Chart
From Apr 2023 to Apr 2024